Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2016 Feb 16;15(4):574–582. doi: 10.1158/1535-7163.MCT-15-0467

Figure 5. CTX1 demonstrates significant anti-cancer activity in vivo.

Figure 5

NSG mice (n=5 per group) were injected with primary human AML cells by the tail vein (5×106 cells in 100μl of media) and mice were treated with CTX1 (30mg/kg ip) or Nutlin-3 (200mg/kg po) and assessed for survival. Log rank test, p<0.0001.